Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
about
Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisManagement of refractory Pseudomonas aeruginosa infection in cystic fibrosisAntibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibioticsSafety of high-dose doripenem in adult patients with cystic fibrosisTobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Clinical Isolates of Pseudomonas aeruginosa from Chronically Infected Cystic Fibrosis Patients Fail To Activate the Inflammasome during Both Stable Infection and Pulmonary Exacerbation.Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.Successful treatment of multiresistant Achromobacter xylosoxidans bacteremia in a child with acute myeloid leukemia.Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen.Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression.
P2860
Q26829604-4D98A1C3-B60B-46CC-A97B-3FFE13E5203DQ35026630-D7C1C306-75FD-4881-89AC-0ADBA6C16B7FQ35542062-51E211B2-30A8-4D9F-BA3D-48162950B8ECQ36232300-A6090459-A245-4914-8D3A-26B0C04B17C6Q36967193-27F37697-7F05-49B7-A2D6-7D160BA1381EQ38358856-8D42BFED-2713-4EBB-9935-F6DDC8E9A425Q38792565-D3AE5B1A-11E9-4208-85B1-1C18C94F06C0Q39071995-4EB5479D-28FD-4ECC-B192-3D667710A2C3Q40813839-0EB1EDFE-18AD-466F-BDCC-7D2A0934FE80Q41018046-72F3E8CF-4B1F-4334-A6B4-31AB47147781Q41563570-A78EA3AA-FBCA-41CF-80FB-D9B3EC83DAF6Q45099898-032A195B-A0D2-4BC2-B0BA-E14301B289D9Q45988832-B6E7F0FA-40B7-487F-903F-395911343162
P2860
Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Newer antibacterial agents and ...... onary exacerbation management.
@en
Newer antibacterial agents and ...... onary exacerbation management.
@nl
type
label
Newer antibacterial agents and ...... onary exacerbation management.
@en
Newer antibacterial agents and ...... onary exacerbation management.
@nl
prefLabel
Newer antibacterial agents and ...... onary exacerbation management.
@en
Newer antibacterial agents and ...... onary exacerbation management.
@nl
P356
P1476
Newer antibacterial agents and ...... onary exacerbation management.
@en
P2093
J S Elborn
M D Parkins
P304
P356
10.1093/JAC/DKQ245
P407
P577
2010-07-06T00:00:00Z